AcuCort AB (ACUC.ST)
AcuCort AB operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Lund, SN, SE. The stock last traded at $0.49, down 1.22% on the session, giving a market capitalisation of $114.2M. Its beta of 1.36 implies it has historically moved more than the broad market.
Specializing in pharmaceutical innovation, AcuCort AB (publ) focuses on the development and commercialization of glucocorticoid dexamethasone film products, particularly for acute allergic conditions. Among its offerings is Zeqmelit, a medication with diverse therapeutic uses. Zeqmelit addresses severe and acute allergic reactions, pediatric croup, chemotherapy-induced nausea and vomiting, and also serves as a treatment for COVID-19 patients who require supplemental oxygen. The company, established in 2006, is headquartered in Lund, Sweden.
AcuCort AB is most often compared with the following Healthcare names: